Sign inJoin waitlistJoin the waitlist

Navin Pinto

Full Member · University of Colorado School of Medicine

Credentials: · · · ·

History

University of Colorado School of Medicine
Present

Hematology and Medical Oncology
2008–2011
Internal Medicine
2005–2008
Saint Louis University School of Medicine
2001–2005

Research

Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Review · Journal of Clinical Oncology · 2015 · First of 13 authors · 697 citations
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
Nature Medicine · 2021 · 285 citations
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an…
The Lancet Oncology · 2020 · Last of 20 authors · 268 citations

Julie Park
25 papers
Susan Cohn
15 papers
Mark Applebaum
11 papers
Steven DuBois
11 papers
Margaret Macy
10 papers
Rochelle Bagatell
10 papers
Nicholas Vitanza
9 papers
Rebecca Gardner
9 papers
Katie Albert
8 papers
Samuel Volchenboum
8 papers
Alanna Church
7 papers
Juliane Gust
7 papers

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029